Ritonavir or saquinavir impairs the invasion of cervical intraepithelial neoplasia cells via a reduction of MMP expression and activity

Objective and design:Treatment of human immunodeficiency virus (HIV)-infected women with the highly active antiretroviral therapy (HAART) has reduced the onset of uterine cervical intraepithelial neoplasia (CIN), and halted its progression to cervical carcinoma. We and others demonstrated that the HIV protease inhibitors (HIV-PIs) used in HAART can exert direct antitumour activities also in HIV-free preclinical or clinical models. As uterine cervical carcinoma is a leading cause of death in women independently of HIV infection, herein we assessed the impact of therapeutic concentrations of HIV-PIs including indinavir (IDV), saquinavir (SQV) or ritonavir (RTV) on cells obtained from CIN or cervical carcinoma lesions of HIV-negative women. Methods:HIV-PI effects were evaluated by cell invasion, growth or toxicity assays, and by RNA, protein or zymogram analyses. Results:Both SQV and RTV inhibited CIN cell invasion, and this was paralleled by a reduced expression and proteolytic activity of the matrix metalloproteinase (MMP)-2 and 9 in treated cells. SQV and RTV also reduced CIN cell growth rate, but did not affect the invasion or growth of cells derived from highly progressed cervical carcinoma. Conclusion:As MMP-2 and MMP-9 have a key role in CIN evolution into cervical carcinoma, these results support the use of SQV or RTV for the block of CIN clinical progression in either HIV-infected or uninfected patients.

[1]  G. Barillari,et al.  Pharmacological management of Kaposi's sarcoma , 2011, Expert opinion on pharmacotherapy.

[2]  T. Kwok,et al.  Human papillomavirus type 16 E6 induces cervical cancer cell migration through the p53/microRNA-23b/urokinase-type plasminogen activator pathway , 2011, Oncogene.

[3]  Di Chen,et al.  Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. , 2011, Current cancer drug targets.

[4]  G. Gray,et al.  Progression and regression of premalignant cervical lesions in HIV-infected women from Soweto: a prospective cohort , 2011, AIDS.

[5]  C. Gialeli,et al.  Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting , 2011, The FEBS journal.

[6]  B. Monk,et al.  Anti-angiogenesis agents in metastatic or recurrent cervical cancer. , 2010, Gynecologic oncology.

[7]  J. Koch,et al.  Rapid, sensitive, type specific PCR detection of the E7 region of human papillomavirus type 16 and 18 from paraffin embedded sections of cervical carcinoma , 2010, Infectious Agents and Cancer.

[8]  J. Archambault,et al.  Molecular Mechanisms of Human Papillomavirus-Induced Carcinogenesis , 2009, Public Health Genomics.

[9]  S. Ōmura,et al.  Chemical biology of natural indolocarbazole products: 30 years since the discovery of staurosporine , 2009, The Journal of Antibiotics.

[10]  R. Batchu,et al.  Ritonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian cancer cells , 2009, Molecular Cancer.

[11]  P. Monini,et al.  Estimation of HIV incidence in San Francisco , 2009, AIDS.

[12]  S. Franceschi,et al.  Pattern of cancer risk in persons with AIDS in Italy in the HAART era , 2009, British Journal of Cancer.

[13]  U. S. Justesen.  Protease inhibitor plasma concentrations in HIV antiretroviral therapy. , 2008, Danish medical bulletin.

[14]  H. Hollema,et al.  A robust ex vivo model for evaluation of induction of apoptosis by rhTRAIL in combination with proteasome inhibitor MG132 in human premalignant cervical explants , 2008, International journal of cancer.

[15]  J. Goedert,et al.  Cancer risk in people infected with human immunodeficiency virus in the United States , 2008, International journal of cancer.

[16]  H. Ovaa,et al.  Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis , 2008, Molecular Cancer Therapeutics.

[17]  L. Laimins,et al.  Regulation of human papillomavirus type 31 gene expression during the differentiation-dependent life cycle through histone modifications and transcription factor binding. , 2008, Virology.

[18]  P. Wang,et al.  A Significant Elevation of Plasma Level of Matrix Metalloproteinase—9 in Patients With High-Grade Intraepithelial Neoplasia and Early Squamous Cell Carcinoma of the Uterine Cervix , 2007, Reproductive Sciences.

[19]  A. Zoncada,et al.  Reduction of the risk of cervical intraepithelial neoplasia in HIV-infected women treated with highly active antiretroviral therapy. , 2007, Acta bio-medica : Atenei Parmensis.

[20]  V. Bourlier,et al.  Inhibition of Human Preadipocyte Proteasomal Activity by HIV Protease Inhibitors or Specific Inhibitor Lactacystin Leads to a Defect in Adipogenesis, Which Involves Matrix Metalloproteinase-9 , 2007, Journal of Pharmacology and Experimental Therapeutics.

[21]  M. Sogayar,et al.  Higher expression and activity of metalloproteinases in human cervical carcinoma cell lines is associated with HPV presence. , 2006, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[22]  E. Palescandolo,et al.  Evaluation of Antitumoral Properties of the Protease Inhibitor Indinavir in a Murine Model of Hepatocarcinoma , 2006, Clinical Cancer Research.

[23]  C. Palmieri,et al.  AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy , 2006, Current opinion in infectious diseases.

[24]  T. Turpeenniemi‐Hujanen,et al.  Matrix metalloproteinase 9 in the uterine cervix during tumor progression , 2006, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[25]  Rosemarie Mick,et al.  HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. , 2005, Cancer research.

[26]  H. Kitchener,et al.  Specific HIV Protease Inhibitors Inhibit the Ability of Hpv16 E6 to Degrade P53 and Selectively Kill E6-Dependent Cervical Carcinoma Cells In Vitro , 2005, Antiviral therapy.

[27]  E. Benveniste,et al.  Interferon‐γ‐activated STAT‐1α suppresses MMP‐9 gene transcription by sequestration of the coactivators CBP/p300 , 2005 .

[28]  Olivia Keiser,et al.  Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. , 2005, Journal of the National Cancer Institute.

[29]  M. Mostert,et al.  The HIV Protease Inhibitors Nelfinavir and Saquinavir, but Not a Variety of HIV Reverse Transcriptase Inhibitors, Adversely Affect Human Proteasome Function , 2005, Antiviral therapy.

[30]  P. Monini,et al.  Antitumour effects of antiretroviral therapy , 2004, Nature Reviews Cancer.

[31]  Masahiro Inoue,et al.  An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. , 2004, The Journal of clinical investigation.

[32]  C. López-Otín,et al.  Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. , 2004, The International journal of developmental biology.

[33]  C. Lang,et al.  Indinavir impairs protein synthesis and phosphorylations of MAPKs in mouse C2C12 myocytes. , 2004, American journal of physiology. Cell physiology.

[34]  Michelle S. Longworth,et al.  Pathogenesis of Human Papillomaviruses in Differentiating Epithelia , 2004, Microbiology and Molecular Biology Reviews.

[35]  E. Pérez-Cárdenas,et al.  Matrix metalloproteinases‐2, ‐3, and ‐9 secreted by explants of benign and malignant lesions of the uterine cervix , 2004, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[36]  V. Vullo,et al.  Anti-HIV drugs decrease the expression of matrix metalloproteinases in astrocytes and microglia. , 2004, Brain : a journal of neurology.

[37]  S. Chow,et al.  Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer. , 2003, Cancer research.

[38]  P. Monini,et al.  Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth. , 2003, The Lancet. Oncology.

[39]  P. Monini,et al.  HIV protease inhibitors as new treatment options for Kaposi's sarcoma. , 2003, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[40]  J. Sellors,et al.  Screening and management of precancerous lesions to prevent cervical cancer in low-resource settings. , 2003, Asian Pacific journal of cancer prevention : APJCP.

[41]  P. Monini,et al.  HIV protease inhibitors: antiretroviral agents with anti-inflammatory, anti-angiogenic and anti-tumour activity. , 2003, The Journal of antimicrobial chemotherapy.

[42]  C. Galanos,et al.  Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis. , 2002, Cancer research.

[43]  Yasuhito Kato,et al.  Relationship between expression of matrix metalloproteinase-2 and matrix metalloproteinase-9 and invasion ability of cervical cancer cells. , 2002, Oncology reports.

[44]  R. Kudo,et al.  Anti-invasive effect of MMI-166, a new selective matrix metalloproteinase inhibitor, in cervical carcinoma cell lines. , 2002, Gynecologic oncology.

[45]  M. Falchi,et al.  HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma , 2002, Nature Medicine.

[46]  L. Ahdieh,et al.  The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women , 2001, AIDS.

[47]  W. Robinson.  Invasive and preinvasive cervical neoplasia in human immunodeficiency virus-infected women. , 2000, Seminars in oncology.

[48]  B. Davidson,et al.  Expression of Matrix Metalloproteinase-9 in Squamous Cell Carcinoma of the Uterine Cervix—Clinicopathologic Study Using Immunohistochemistry and mRNAin SituHybridization , 1999 .

[49]  S. Motoyama,et al.  Factors Regulating SCC Antigen Expression in Squamous Cell Carcinoma of the Uterine Cervix , 1998, Tumor Biology.

[50]  M. Kazatchkine,et al.  Early regression of cervical lesions in HIV‐seropositive women receiving highly active antiretroviral therapy , 1998, AIDS.

[51]  J. Ward,et al.  Effect of antiretroviral therapy on recent trends in selected cancers among HIV-infected persons. Adult/Adolescent Spectrum of HIV Disease Project Group. , 1998, Journal of acquired immune deficiency syndromes.

[52]  M. Falchi,et al.  Human immunodeficiency virus protease inhibitors reduce the growth of human tumors via a proteasome‐independent block of angiogenesis and matrix metalloproteinases , 2011, International journal of cancer.

[53]  Min Guan,et al.  Anti-HIV drugs for cancer therapeutics: back to the future? , 2009, The Lancet. Oncology.

[54]  A. Daneri-Navarro,et al.  Protease-activated receptor-2 (PAR-2) in cervical cancer proliferation. , 2008, Gynecologic oncology.

[55]  A. Baldi,et al.  Effects of indinavir in a preliminary phase I study on dogs with stage III slenic hemangiosarcoma. , 2006, In vivo.

[56]  I. El-Lamie,et al.  Expression of matrix metalloproteinase-2 in preinvasive and invasive carcinoma of the uterine cervix. , 2005, European journal of gynaecological oncology.

[57]  E. Benveniste,et al.  Interferon-gamma-activated STAT-1alpha suppresses MMP-9 gene transcription by sequestration of the coactivators CBP/p300. , 2005, Journal of leukocyte biology.

[58]  B. Davidson,et al.  Expression of matrix metalloproteinase-9 in squamous cell carcinoma of the uterine cervix-clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. , 1999, Gynecologic oncology.

[59]  Title: Evaluation of Bioactive Sphingolipids in 4-hpr-resistant Leukemia Cells , 2022 .